Surgical Outcome of Patients Undergoing Pancreaticoduodenectomy: Analysis of a 17‒Year Experience at a Single Center.
Kosei Takagi(Okayama Shoka University), Toshiyoshi Fujiwara(Okayama University), Kenta Sui(Okayama University), Daisuke Nobuoka(Fukuyama City Hospital), Susumu Shinoura(Okayama University), Nobuyuki Watanabe(Okayama University), Takashi Kuise(Okayama Red Cross General Hospital), Takahito Yagi(Okayama University), Yuzo Umeda(Okayama University), Tomokazu Fuji(Okayama University), Ryuichi Yoshida(Okayama University)
Cited by 13
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer
|JCI Insight|2018|148
The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer
|Journal of Experimental & Clinical Cancer Research|2018|111